Received May 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| IPV | POLIO VIRUS, INACT. (IPOL) | SANOFI PASTEUR | UNK | — | — |
received the first dose of IPOL at 22 months and second dose at 27 months. The third dose was given as DTaP-IPV combination at 5 years old with no adverse event; Initial information received on 07-May-2026 regarding an unsolicited valid non-serious case received from an other or unknown healthcare professional (HCP). This case involves a 15-year-old female patient who received the first dose of Poliomyelitis Vaccine (Inactivated) [Ipol] (Ipol) at 22 months and second dose at 27 months. The third dose was given as DTaP-IPV combination at 5 years old with no adverse event. The patient's past medical history, past drugs, vaccination(s), family history, and concomitant medications were not provided. On an unknown date, the patient received an unknown dose of Poliomyelitis Vaccine (Inactivated) [Ipol], suspension for injection (batch/lot number: unknown; expiry: unknown) (strength: unknown) via unknown route in an unknown administration site for immunization [Immunisation]. Caller called to inquire whether the patient needed more doses of IPOL vaccination, as it was not up to date, or if the patient was past the marker where it was too late. The reporter stated that the patient received the first dose of IPOL at 22 months and second dose at 27 months. The third dose was given as DTaP-IPV (diphtheria, tetanus, acellular pertussis, and inactivated poliovirus) combination at 5 years old with no adverse event. The patient received 3 doses in total, and the office coordinator was uncertain whether the patient needed 4 doses. The office coordinator declined to provide any patient information and stated that she would discuss it first with the provider. The office coordinator verbally consented to a follow-up in case the safety team wanted additional information. No further information was provided by the office coordinator. The patient received the first dose of IPOL at 22 months and second dose at 27 months. The third dose was given as DTaP-IPV combination at 5 years old with no adverse event (Inappropriate schedule of product administration, onset: unknown and latency: unknown). Action taken: not applicable. Disclaimer: This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Comments: NONE